834869-04-4 Usage
Uses
Used in Pharmaceutical Industry:
7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile is used as a key intermediate in the synthesis of various pharmaceutical products. Its unique structure and properties contribute to the development of new drugs, enhancing their therapeutic potential and efficacy.
Used in Agrochemical Industry:
In the agrochemical sector, 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile serves as a crucial building block for the synthesis of agrochemical products. Its incorporation into these products helps improve their performance and effectiveness in agricultural applications.
Used in Chemical Research:
7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile is utilized as a valuable tool in chemical research. Its unique structure allows researchers to explore new chemical reactions and mechanisms, contributing to the advancement of scientific knowledge in the field.
Used in Organic Synthesis:
As an intermediate in organic synthesis, 7-Methoxyimidazo[1,2-a]pyridine-8-carbonitrile is employed for the preparation of other complex organic compounds. Its versatility and reactivity make it an essential component in the synthesis of a wide range of organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 834869-04-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,4,8,6 and 9 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 834869-04:
(8*8)+(7*3)+(6*4)+(5*8)+(4*6)+(3*9)+(2*0)+(1*4)=204
204 % 10 = 4
So 834869-04-4 is a valid CAS Registry Number.
834869-04-4Relevant academic research and scientific papers
IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
-
Page/Page column 77, (2009/04/25)
rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
